|
|
Post by peppy on May 13, 2018 7:11:49 GMT -5
On the horizon Some of the most theoretical ideas also have the potential to be the most disruptive. One is to upend the existing rebate system, in which drug companies pay rebates, or discounts, off the list price to insurers and employers. But those rebates are often considered trade secrets, and pharmacy-benefit managers pocket a portion of the rebate for themselves, creating what many have described as perverse incentives that keep drug prices rising. The Trump administration has said it is examining whether it should consider rebates to be a form of illegal kickback, a change that would likely require congressional action. www.nytimes.com/2018/05/11/health/trump-drug-prices.htmlOn the other hand, there comes the risk of "blowback." Take away the rebates/kickbacks and how much will health insurance rates climb in consequence? My own is averaging about a 10% increase a year. just looking at reasons why volume came in strong on a Friday after noon. You know the old adage, the market knows way before you do. My take, he wants to do something, as we have seen, he leans towards putting pressure on people he sees as underpaying, in this case Europe. He would like Europe to pay up, his typical behavior. How? How to make Europe/international pay more? If the rebate pressure would give American countries equal footing of some sort? Just talking out loud here, looking for the reason for the Friday afternoon pop. "The theme of the president’s initiative is “American patients first,” and his plan takes aim at what the White House calls “foreign freeloading.” The administration will, as expected, put pressure on foreign countries to relax drug price controls, in the belief that pharmaceutical companies can then lower prices in the United States. “Other countries use socialized health care to command unfairly low prices from U.S. drugmakers,” said a summary provided by the White House on Thursday. “This places the burden of financing drug development largely on American patients and taxpayers, subsidizes foreign consumers, and reduces innovation and the development of new treatments.” The United States spends well over $300 billion a year on prescription drugs sold at pharmacies and other retail outlets, and Medicare and Medicaid account for nearly 40 percent of that spending, according to the Department of Health and Human Services. Mr. Trump plans to criticize brand-name drug manufacturers for setting high list prices and for trying to stifle competition by delaying the marketing of lower-cost generic drugs. He is also expected to criticize pharmacy benefit managers, saying they profit from rebates paid by drug companies but do not pass on much of the savings to patients. Mr. Trump has repeatedly said that drug companies are “getting away with murder.” In his State of the Union address in January, he said that “fixing the injustice of high drug prices” was one of his top priorities for 2018. “And prices will come down substantially,” he said. “Watch.” " |
|
|
|
Post by agedhippie on May 13, 2018 10:14:55 GMT -5
On the other hand, there comes the risk of "blowback." Take away the rebates/kickbacks and how much will health insurance rates climb in consequence? My own is averaging about a 10% increase a year. ... "The theme of the president’s initiative is “American patients first,” and his plan takes aim at what the White House calls “foreign freeloading.” The administration will, as expected, put pressure on foreign countries to relax drug price controls, in the belief that pharmaceutical companies can then lower prices in the United States. “Other countries use socialized health care to command unfairly low prices from U.S. drugmakers,” said a summary provided by the White House on Thursday. “This places the burden of financing drug development largely on American patients and taxpayers, subsidizes foreign consumers, and reduces innovation and the development of new treatments.” Lets take the EU as an example here. The UK NHS pays a fraction of the price for insulin that the US does (about 15%). This is because the NHS negotiates, not because there are price controls. The insulin companies do not have to sell to the the NHS, in fact Novo Nordisk declined to sell Tresiba to one of the German health systems because they couldn't get the price they wanted. Prices in the US are higher because the pharmas can get higher prices. The insurance system makes a large chunk of the population price insensitive, I don't care if the list price on my insulin is $500 or $50 per month, my co-pay is $20 regardless. Would I like more choice? Definitely. Would I be prepared to pay significantly more for that choice? No. Of course this means everyone on high deductible plans, or no insurance at all is collateral damage as the insurers/PBMs/pharmas/lawmakers dance to keep prices high for maximum profit from plans like mine. |
|
|
|
Post by peppy on May 14, 2018 7:47:14 GMT -5
|
|
|
|
Post by peppy on May 15, 2018 14:08:31 GMT -5
an hour left in the trading day. MNKD shares are low volume, 899,275 shares traded real time. $1.90. the measured move of 2.20 still in the works. if and when, price will have popped the wedge from 6 dollars to 1.62. The $SPX down 24 points at the moment. MNKD has started it's share price increase for the ADA? Just throwing it out in the atmosphere. www.nasdaq.com/symbol/mnkd/real-time |
|
|
|
Post by traderdennis on May 15, 2018 14:15:33 GMT -5
an hour left in the trading day. MNKD shares are low volume, 899,275 shares traded real time. $1.90. the measured move of 2.20 still in the works. if and when, price will have popped the wedge from 6 dollars to 1.62. The $SPX down 24 points at the moment. MNKD has started it's share price increase for the ADA? Just throwing it out in the atmosphere. www.nasdaq.com/symbol/mnkd/real-timeI think there is a good possibility we are starting the rise to ADA. I am starting to layer a swing long. |
|
|
|
Post by cjm18 on May 15, 2018 15:25:00 GMT -5
an hour left in the trading day. MNKD shares are low volume, 899,275 shares traded real time. $1.90. the measured move of 2.20 still in the works. if and when, price will have popped the wedge from 6 dollars to 1.62. The $SPX down 24 points at the moment. MNKD has started it's share price increase for the ADA? Just throwing it out in the atmosphere. www.nasdaq.com/symbol/mnkd/real-timeI think there is a good possibility we are starting the rise to ADA. I am starting to layer a swing long. Wow ada is still over a month away. I was thinking it was the run up to tomorrow’s meeting. Mannkind was at 2016 ada but it was late breaking almost the day of. Could we have more late breaking posters (secondary end points of the stat study)? The stock did go up after the 2016 ada meeting before going back down. |
|
|
|
Post by celo on May 15, 2018 15:33:18 GMT -5
an hour left in the trading day. MNKD shares are low volume, 899,275 shares traded real time. $1.90. the measured move of 2.20 still in the works. if and when, price will have popped the wedge from 6 dollars to 1.62. The $SPX down 24 points at the moment. MNKD has started it's share price increase for the ADA? Just throwing it out in the atmosphere. www.nasdaq.com/symbol/mnkd/real-time2.20 seems to be the top of the wedge. Nice to see it breakout with good news tomorrow. Could be a few different items discussed here. Small ascending channel over the last month, points to someone acquiring (a small amount) shares for a move upward. We shall see. Have a good time tomorrow, everyone. www.tradingview.com/x/IR4h1WT9/ |
|
|
|
Post by peppy on May 15, 2018 16:16:43 GMT -5
My chart is looking at price differently than your chart.
one pattern leading into the next.
a triangle, that popped@ 1.77 with a target of 2.20 which leads to the wedge break.
we will see.
1,166,429 shares traded real time on nasdaq.
$1.88 unchanged.
1,742,732 shares nasdaq summary volume.
|
|
|
|
Post by traderdennis on May 15, 2018 17:12:52 GMT -5
I think there is a good possibility we are starting the rise to ADA. I am starting to layer a swing long. Wow ada is still over a month away. I was thinking it was the run up to tomorrow’s meeting. Mannkind was at 2016 ada but it was late breaking almost the day of. Could we have more late breaking posters (secondary end points of the stat study)? The stock did go up after the 2016 ada meeting before going back down. Run up on stat was at least a month. And by layeriimg my size currently is about 20percent of where it may end oup |
|
|
|
Post by peppy on May 15, 2018 18:00:00 GMT -5
Wow ada is still over a month away. I was thinking it was the run up to tomorrow’s meeting. Mannkind was at 2016 ada but it was late breaking almost the day of. Could we have more late breaking posters (secondary end points of the stat study)? The stock did go up after the 2016 ada meeting before going back down. Run up on stat was at least a month. And by layeriimg my size currently is about 20percent of where it may end oup the set up. a small triangle measuring to 2.20 takes price over the downtrending price wedge. $2.05 resistance. it is the wedge we want price to break = the downtrend line from $6.96. |
|
|
|
Post by kite on May 17, 2018 11:29:19 GMT -5
Come on $2.05!
|
|
|
|
Post by awesomo on May 17, 2018 12:30:12 GMT -5
Good volume today (2M+), steady increase, breached $2.
|
|
|
|
Post by casualinvestor on May 17, 2018 14:21:20 GMT -5
Because of option expiration tomorrow, I think it will be held under $2 through friday unless there are a bunch of buyers
|
|
|
|
Post by traderdennis on May 17, 2018 15:23:51 GMT -5
Because of option expiration tomorrow, I think it will be held under $2 through friday unless there are a bunch of buyers About 430K shares on the 2.00 call and 106K shares on the 2.00 put. Probably not enough shares to manipulate pricing on, I don't think we will see a pin tomorrow. |
|
|
|
Post by peppy on May 17, 2018 15:38:36 GMT -5
MNKD Nasdaq real time trading volume, 1,997,529 shares. MNKD Nasdaq summary , Share Volume 2,962,517. MNKD $1.99 +0.08. +4.19% 2.00 is a gap 2.20 fills the gap. options expiry tomorrow. www.nasdaq.com/symbol/mnkd |
|
